

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>GOEDEL DAVID V</u>  (Last) (First) (Middle) C/O RAPT THERAPEUTICS, INC. 561 ECCLES AVENUE  (Street) SOUTH SAN FRANCISCO CA 94080  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/30/2019	3. Issuer Name and Ticker or Trading Symbol <u>RAPT Therapeutics, Inc. [ RAPT ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	50,000 <sup>(1)</sup>	I	By The Column Group II Management, LP <sup>(2)(3)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(4)	(4)	Common Stock	2,463,659 <sup>(1)</sup>	(4)	I	By The Column Group II, LP <sup>(3)(5)</sup>
Series B Preferred Stock	(4)	(4)	Common Stock	1,166,666 <sup>(1)</sup>	(4)	I	By The Column Group II, LP <sup>(3)(5)</sup>
Series C Preferred Stock	(4)	(4)	Common Stock	727,008 <sup>(1)</sup>	(4)	I	By The Column Group II, LP <sup>(3)(5)</sup>
Series C Preferred Stock	(4)	(4)	Common Stock	1,454,016 <sup>(1)</sup>	(4)	I	By Pono Capital, LP <sup>(3)(6)</sup>
Series C-2 Preferred Stock	(4)	(4)	Common Stock	145,401 <sup>(1)</sup>	(4)	I	By Pono Capital, LP <sup>(3)(6)</sup>
Series C-2 Preferred Stock	(4)	(4)	Common Stock	145,401 <sup>(1)</sup>	(4)	I	By Pono Capital II, LP <sup>(3)(7)</sup>

**Explanation of Responses:**

- The number of shares of common stock reflects a 1-for-6 reverse stock split, which became effective July 19, 2019.
- These shares are held directly by The Column Group II Management, LP.
- David Goedel is a managing partner of The Column Group II GP, LP, which is the general partner of The Column Group II, LP. Dr. Goedel is also a managing partner of The Column Group II Management, LP. Dr. Goedel is also a managing partner of Pono Management, LLC, general partner of Pono Capital, LP, and a managing partner of Pono II Management, LLC, general partner of Pono Capital II, LP. Dr. Goedel may be deemed to share voting and investment power with respect to the shares reported herein and disclaims beneficial ownership of the shares except to the extent of his pecuniary interests therein.
- Each share of Series A, Series B, Series C and Series C-2 Preferred Stock is convertible into approximately 0.166 shares of the Issuer's common stock upon the closing of the Issuer's initial public offering (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019). Shares of Series A, Series B, Series C and Series C-2 Preferred Stock have no expiration date and will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering of common stock, for no additional consideration.
- These shares are held directly by The Column Group II, LP.
- These shares are held directly by Pono Capital, LP.
- These shares are held directly by Pono Capital II, LP.

**Remarks:**

/s/ Karen C. Lam, attorney-in-  
fact for David V. Goeddel 10/30/2019

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of BRIAN WONG, KAREN C. LAM and MICHAEL TENTA, signing individually, the undersigned's true and lawful attorneys-in-fact and agents to:

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of RAPT THERAPEUTICS, INC. (the "Company"), Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder and a Form ID, Uniform Application for Access Codes to File on EDGAR;

(2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to execute such Forms 3, 4 or 5 or Form ID (including any amendments thereto) and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or Cooley LLP.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of July 11, 2019.

/s/ David V. Goeddel  
David V. Goeddel, Ph.D.